Molecular basis of aggressive disease in chronic lymphocytic leukemia patients with 11q deletion and trisomy 12 chromosomal abnormalities

International Journal of Molecular Medicine

Volumn 20, Issue 4, 2007, Pages 461-469

  Mittal, Amit K ^a   Hegde, Ganapati V ^a   Aoun, Patricia ^b   Bociek, Robert G ^b   Dave, Bhavana J ^c   Joshi, Avadhut D ^a   Sanger, Warren G ^c   Weisenburger, Dennis D ^b   Joshi, Shantaram S ^a  

^a NEBRASKA MEDICAL CENTER   (United States)

^b UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

^c UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

Author keywords

11q deletion; ATF5; Chromosomal abnormalities; Chronic lymphocytic leukemia; Trisomy 12

Indexed keywords

ACTIVATING TRANSCRIPTION FACTOR; ATF5 PROTEIN, HUMAN; UNCLASSIFIED DRUG;

ARTICLE; B CELL LEUKEMIA; CHROMOSOME 11; CHROMOSOME 12; CHROMOSOME ANALYSIS; CHROMOSOME DELETION; CLUSTER ANALYSIS; DISEASE COURSE; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENETICS; HUMAN; MALE; METABOLISM; MIDDLE AGED; PATHOLOGY; PROGNOSIS; TIME; TREATMENT OUTCOME; TRISOMY; TUMOR GENE;

ACTIVATING TRANSCRIPTION FACTORS; CHROMOSOME DELETION; CHROMOSOMES, HUMAN, PAIR 11; CHROMOSOMES, HUMAN, PAIR 12; CLUSTER ANALYSIS; CYTOGENETIC ANALYSIS; DISEASE PROGRESSION; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, NEOPLASM; HUMANS; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; MALE; MIDDLE AGED; PROGNOSIS; TIME FACTORS; TREATMENT OUTCOME; TRISOMY;

EID: 38449114255     PISSN: 11073756     EISSN: 1791244X     Source Type: Journal    
DOI: 10.3892/ijmm.20.4.461     Document Type: Article

References (24)

1. Rozman C and Montserrat E: Chronic lymphocytic leukemia. N Engl J Med 1333: 1052-1057, 1995.
2. Zwiebel JA and Cheson BD: Chronic lymphocytic leukemia: staging and prognostic factors. Semin Oncol 25: 42-59, 1998.
3. Schroers R, Griesinger F, Trümper L, Haase D, Kulle B, Klein-Hitpass L, Sellmann L, Dührsen U and Dürig J: Combined analysis of ZAP-70 and CD38 expression as a predictor of disease progression in B-cell chronic lymphocytic leukemia. Leukemia 19: 750-758, 2005.
4. Rai KR, Sawitsky A, Cronkite EP, Chanana AD, Levy RN and Paternack BS: Clinical staging of chronic lymphocytic leukemia. Blood 46: 219-234, 1975.
5. Binet JL, Auquier A, Dighiero G, et al: A new prognostic classification of chronic lymphocytic leukemia derived from a multivariate survival analysis. Cancer 48: 198-206, 1981.
6. Keating MJ, Chiorazzi N, Messmer B, Damle RN, Allen SL, Rai KR, et al: Biology and Treatment of Chronic Lymphocytic Leukemia. ASH Educational Book (The American Society of Hematology), pp153-175, 2003.
7. Shanafelt TD, Geyer SM and Kay NE: Prognosis at diagnosis: integrating molecular biologic insights into clinical practice for patients with CLL. Blood 103: 1202-1210, 2004.
8. Hamblin TJ, Davis Z, Gardiner A, Oscier DG and Stevenson FK: Unmutated IgV(H) genes are associated with a more aggressive form of chronic lymphocytic leukemia. Blood 94: 1848-1854, 1999.
9. Damle RN, Wasil T, Fais F, Ghiotto F, Valetto A, Allen SL, et al: IgV gene mutation status and CD38 expression as novel prognostic indicators in chronic lymphocytic leukemia. Blood 94: 1840-1847, 1999.
10. Döhner H, Stilgenbauer S, Benner A, et al: Genomic aberrations and survival in chronic lymphocytic leukemia. N Engl J Med 343: 1910-1918, 2000.
11. Dickinson JD, Smith LM, Sanger WG, Zhou G, Townley P, Lynch JC, Pavletic ZS, Bierman PJ and Joshi SS: Unique gene expression and clinical characteristics are associated with the 11q23 deletion in chronic lymphocytic leukaemia. Br J Haematol 128: 460-471, 2005.
12. Joshi AD, Dickinson JD, Hedge GV, Sanger WG, Armitage JO, Bierman PJ, Bociek RG, de Vetten MP, Vose JM and Joshi SS: Bulky lymphadenopathy with poor clinical outcome is associated with ATM down regulation in CLL patients irrespective of 11q23 deletion. Cancer Genet Cytogenet 172: 120-126, 2006.
13. Krober A, Seiler T, Benner A, Bullinger L, Brückle E, Lichter P, Döhner H and Stilgenbauer S: VH mutation status, CD38 expression level, genomic aberrations, and survival in chronic lymphocytic leukemia. Blood 100: 1410-1416, 2002. (Pubitemid 34864299)
14. Wang P, Munger CM, Joshi AD, Pirruccello SJ and Joshi SS: Cytotoxicity of cord blood derived Her2/neu-specific cytotoxic T lymphocytes against human breast cancer in vitro and in vivo. Breast Cancer Res Treat 83: 15-23, 2004.
15. Aoun P, Blair HE, Smith LM, Dave BJ, Lynch J, Weisenburger DD, Pavletic ZS and Sanger WG: Fluorescence in situ hybridization detection of cytogenetic abnormalities in B-cell chronic lymphocytic leukemia/small lymphocytic lymphoma. Leuk Lymphoma 45: 1595-1603, 2004.
16. Dewald GW, Brockman SR, Paternoster SF, Bone ND, O'Fallon JR, Allmer C, James CD, Jelinek DF, Tschumper RC, Hanson CA, Pruthi RK, Witzig TE, Call TG and Kay NE: Chromosome anomalies detected by interphase fluorescence in situ hybridization: correlation with significant biological features of B-cell chronic lymphocytic leukaemia. Br J Haematol 121: 287-295, 2003.
17. Dohner H, Stilgenbauer S, Dohner K, Bentz M and Lichter P: Chromosome aberrations in B-cell chronic lymphocytic leukemia: reassessment based on molecular cytogenetic analysis. J Mol Med 77: 266-281, 1999.
18. Stilgenbauer S, Lichter P and Dohner H: Genetics of chronic lymphocytic leukemia: genomic aberrations and VH gene mutation status in pathogenesis and clinical course. Leukemia 16: 993-1007, 2002. (Pubitemid 34618838)
19. Angelastro JM, Ignatova TN, Kukekov VG, Steindler DA, Stengren GB, Mendelsohn C and Greene LA: Regulated expression of ATF5 is required for the progression of neural progenitor cells to neurons. J Neurosci 23: 4590-4600, 2003.
20. Peters CS, Liang X, Li S, Kannan S, Peng Y, Taub R and Diamond H: ATF-7, a novel bZIP protein, interacts with the PRL-1 protein-tyrosine phosphatase. J Biol Chem 276: 13718-13726, 2001.
21. Persengiev SP, Devireddy LR and Green MR: Inhibition of apoptosis by ATFx: a novel role of member of the ATF/CREB family of mammalian bZIP transcription factors. Genes Dev 16: 1806-1814, 2002.
22. Gricks CS, Zahrieh D, Zauls AJ, Gorgun G, Drandi D, Mauerer K, Neuberg D and Gribben JG: Differential regulation of gene expression following CD40 activation of leukemic compared to healthy B cells. Blood 104: 4002-4009, 2004.
23. Stratowa C, Loffler G, Lichter P, Stilgenbauer S, Haberl P, Schweifer N, et al: c-DNA microarray gene expression analysis of B-cell chronic lymphocytic leukemia proposes potential new prognostic markers involved in lymphocyte trafficking. Int J Cancer 91: 474-480, 2001. (Pubitemid 32115100)
24. Woo IS, Kohno T, Inoue K, Ishii S and Yokota J: Infrequent mutations of the activating transcription factor-2 gene in human lung cancer, neuroblastoma and breast cancer. Int J Oncol 20: 527-531, 2002.